Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in Recurrent IgG4-related Disease
NCT05728684Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of stapokibart in IgG4-related disease (IgG4-RD), sponsored by Beijing Friendship Hospital. Primary endpoint: Response rate at 12 weeks. Status: unknown.
02
Drugs
stapokibart
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT05728684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728684.